Reference:
European Medicines Agency. (2021). Assessment report on the annual renewal of the conditional marketing authorisation. EMA/596333/2021.
Summary:
The European Medicines Agency (EMA) assessed the annual renewal of the conditional marketing authorisation for Comirnaty, a COVID-19 mRNA vaccine developed by BioNTech. Initially granted on 21 December 2020, the renewal process involved reviewing specific obligations (SOBs) and evaluating the safety, efficacy, and quality of the vaccine. The assessment included data from clinical trials, compliance with manufacturing processes, and pharmacovigilance activities. The CHMP identified several ongoing SOBs, particularly regarding the quality control of excipients and the necessity for additional data on product efficacy. Despite some outstanding obligations, the overall benefit-risk balance for Comirnaty was deemed positive, supporting its continued use in the population aged 12 years and older. The report concluded that no changes to the product information were required and recommended the renewal of the marketing authorisation, emphasising the need for ongoing safety monitoring.